| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $3.5M | +20.6% |
| Cost of Revenue | $1.2M | -39.5% |
| R&D Expense | $2.0M | -38.0% |
| SG&A Expense | $6.1M | +5.5% |
| Operating Income | -$5.9M | +28.3% |
| Net Income | -$5.8M | +14.5% |
| EPS (Basic) | -$0.20 | +16.7% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $6.5M | -0.1% |
| Short-term Investments | $2.8M | — |
| Accounts Receivable | $237K | -49.2% |
| Current Assets | $9.8M | +21.8% |
| Total Assets | $9.9M | +20.8% |
| Current Liabilities | $2.4M | +8.7% |
| Total Liabilities | $7.5M | +218.7% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$4.0M | +40.9% |
| Investing Cash Flow | -$1.9M | -125.2% |
| Financing Cash Flow | $5.8M | — |
| Stockholders' Equity |
| $2.5M |
| -58.0% |